US2020225240A1PendingUtilityA1

Use of cd36 to identify cancer subjects for treatment

71
Assignee: CHILDRENS MEDICAL CENTERPriority: Mar 14, 2013Filed: Aug 23, 2019Published: Jul 16, 2020
Est. expiryMar 14, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Randolph S. Watnick
G01N 33/5759C12Q 1/6886C07K 5/12A61K 38/18C12Q 2600/106G01N 2800/52A61P 35/00A61K 47/6811A61P 35/02A61K 38/1709G01N 2333/70596C12Q 2600/158G01N 33/57492
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for evaluating a subject' s responsiveness to treatment ith a Psap peptide, the method comprising:
 determining a level of CD36 in a sample obtained from a subject having cancer, wherein an elevated level of CD36 in the sample compared to a control level indicates that the subject is responsive to or likely to be responsive to treatment with a Psap peptide.   
     
     
         2 - 33 . (canceled)

Join the waitlist — get patent alerts

Track US2020225240A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.